Lilly starts RENEW-IBS-D, a Phase 2 trial of brenipatide in irritable bowel syndrome

Eli Lilly has begun enrolling patients in a Phase 2 clinical trial of brenipatide, an experimental drug also known by its code name LY3537031, for people with irritable bowel syndrome with diarrhea, or IBS-D ^[1]. The trial, registered as NCT07545759 and named RENEW-IBS-D, plans to enroll 531 adults ^[1].

Brenipatide belongs to the same broad family of incretin-based compounds that includes semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), drugs that work on gut hormone pathways tied to appetite and blood sugar ^[1]. Testing one of these compounds in IBS-D, a digestive condition marked by abdominal pain and frequent loose stools, shows Lilly is trying to stretch incretin chemistry into gastrointestinal disease rather than only metabolic conditions like diabetes and obesity ^[1].

The study listing on ClinicalTrials.gov gives basic facts: the drug name, the participant target of 531 adults, and the condition being studied, IBS-D ^[1]. It does not yet make public the exact dose levels, how long people will be treated, or what specific symptom measures will count as success. Those details are not yet known from the information available.

IBS-D is a common but hard-to-treat digestive disorder. Current treatment options for the condition are limited, and many patients cycle through several drugs or dietary changes before finding something that helps. A new mechanism, if it works, could give doctors and patients another option. But Phase 2 is an early testing stage. Most drugs that enter Phase 2 trials do not end up reaching pharmacy shelves, and no results from this trial are available yet.

Why it matters for patients

For people who already take semaglutide or tirzepatide for diabetes or weight management, this trial does not change anything about their current prescriptions. Brenipatide is a separate, unapproved compound being tested for a different condition, IBS-D, not for diabetes or obesity ^[1].

For people living with IBS-D, the trial signals that a major drugmaker sees enough scientific reason to test incretin-pathway drugs for gut symptoms beyond blood sugar and weight. That does not mean a new treatment is close. Phase 2 trials are designed to check safety and look for early signs that a drug works at a given dose, not to confirm long-term effectiveness. Results, if the trial finishes as planned, would still need to be followed by a larger Phase 3 trial and a Food and Drug Administration review before any approval for IBS-D could happen.

Patients considering whether to join a clinical trial, or wondering how this development might affect their own care, do not have enough information yet from public sources to know timelines for results or what the trial's specific safety findings might show. Anyone interested in enrollment details, eligibility, or study sites can find that information directly through the ClinicalTrials.gov listing for NCT07545759 ^[1].

What happens next

The trial listing indicates enrollment is underway, with a target of 531 adult participants ^[1]. As is standard for registered trials, further updates such as completion dates, detailed dosing arms, and eventual results are expected to be posted to the same ClinicalTrials.gov record over time, though no such results are available as of now ^[1]. Until data are reported, it remains unknown whether brenipatide will show meaningful benefit for IBS-D symptoms or what side effects may emerge in this patient population.